DUBLIN – Shares in Argenx NV rose as much as 15 percent Monday on news of an oncology license agreement with the Cilag GmbH International arm of Johnson & Johnson involving its CD70-directed antibody cusatuzumab, in which it is receiving $300 million up front plus another $200 million as equity investment. Argenx could also receive up to $1.3 billion more in development, regulatory and sales milestones, while retaining the right to co-promote the drug in the U.S on a 50/50 basis. It would receive tiered double-digit royalties on ex-U.S. sales.